On November 6, 2019 argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, reported three presentations at the the upcoming 61st American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting being held from December 7-10, 2019 in Orlando, FL (Press release, argenx, NOV 6, 2019, View Source [SID1234550437]). The presentations will include preclinical translational data highlighting the multiple modes of action of cusatuzumab to target leukemic stem cells, potential synergies of cusatuzumab in combination with a BCL-2 antagonist, and previously announced data from the Company’s completed Phase 2 trial of efgartigimod for primary immune thrombocytopenia (ITP).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details for the oral presentations are as follows:
Title: Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans
Oral Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targets and Combinations
Date and Time: Saturday, December 7, 3:15 p.m. ET
Location: Orange County Convention Center, Chapin Theater, W320
Presenter: Dr. Adrian Ochsenbein, M.D., University of Bern
Title: Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia
Oral Session: 311. Disorders of Platelet Number or Function: Advances in ITP Therapy
Date and Time: Monday, December 9, 6:15 p.m. ET
Location: Orange County Convention Center, W307
Presenter: Dr. Adrian Newland, M.D., The Royal London Hospital
Details for the poster presentation are as follows:
Title: The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Date & Time: Monday, December 9, 2019, 6:00 p.m. – 8:00 p.m. ET
Location: Orange County Convention Center, Hall B
Presenter: Dr. Carsten Riether, Ph.D., University of Bern